| | | | | | | | | | | | | | | | | | | | | |
<?xml version="1.0" encoding="windows-1252"?> |
<!-- XBRL document created with Toppan Merrill Bridge 9.6.8167.22744 --> |
<!-- Based on XBRL 2.1 --> |
<!-- Created on: 8/2/2022 9:33:26 AM --> |
<!-- Modified on: 8/2/2022 9:33:26 AM --> |
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance"> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#StatementCondensedConsolidatedStatementsOfCashFlow" roleURI="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureBasisOfPresentation" roleURI="http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureFairValueMeasurements" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureMarketableSecurities" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureIntangibleAssets" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureOtherLongTermLiabilities" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockholdersEquity" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockBasedCompensation" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureAccumulatedOtherComprehensiveIncome" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureRevenue" roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureIncomeTaxes" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureNetLossPerShare" roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureKolltanAcquisition" roleURI="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisition" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureMarketableSecuritiesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureOtherLongTermLiabilitiesTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureAccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureIntangibleAssetsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureOtherLongTermLiabilitiesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockBasedCompensationExpensesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureStockBasedCompensationValuationDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureAccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureRevenueDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <roleRef xlink:type="simple" xlink:href="cldx-20220630.xsd#DisclosureKolltanAcquisitionDetails" roleURI="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails" xmlns="http://www.xbrl.org/2003/linkbase"/> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637950296049653019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637950296049653019" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637950296049653019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637950296049653019" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637950296049653019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637950296049653019" order="3" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637950296049653019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637950296049653019" order="4" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637950296049663030" order="5" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637950296049663030" order="6" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637950296049663030" order="7" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637950296049663030" order="8" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637950296049663030" order="9" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3_637950296049663030" order="10" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637950296049663030" order="11" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637950296049663030" order="12" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637950296049663030" order="13" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637950296049663030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637950296049663030" order="14" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637950296049673079" order="15" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637950296049673079" order="16" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637950296049673079" order="17" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637950296049673079" order="18" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637950296049673079" order="19" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637950296049673079" order="20" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637950296049673079" order="21" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637950296049673079"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637950296049673079" order="22" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637950296049683023" order="23" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637950296049683023" order="24" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637950296049683023" order="25" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637950296049683023" order="26" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637950296049683023" order="27" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637950296049683023" order="28" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637950296049683023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637950296049683023" order="29" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637950296049693012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637950296049693012" order="30" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637950296049693012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637950296049693012" order="31" use="optional"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637950296049693012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637950296049693012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637950296049693012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637950296049693012" xlink:to="us-gaap_AssetsCurrentAbstract_637950296049693012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637950296049693012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637950296049693012" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637950296049693012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637950296049693012" xlink:to="us-gaap_MarketableSecuritiesCurrent_637950296049703027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637950296049693012" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_637950296049703027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637950296049693012" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637950296049703027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637950296049693012" xlink:to="us-gaap_AssetsCurrent_637950296049703027" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637950296049693012" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637950296049703027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637950296049693012" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637950296049703027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637950296049693012" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_637950296049703027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637950296049693012" xlink:to="us-gaap_OtherAssetsNoncurrent_637950296049703027" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637950296049693012" xlink:to="us-gaap_Assets_637950296049703027" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" xlink:to="us-gaap_AccountsPayableCurrent_637950296049713025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637950296049713025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_LitigationSettlementPayable" xlink:label="cldx_LitigationSettlementPayable_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" xlink:to="cldx_LitigationSettlementPayable_637950296049713025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637950296049713025" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" xlink:to="us-gaap_OtherLiabilitiesCurrent_637950296049713025" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637950296049713025" xlink:to="us-gaap_LiabilitiesCurrent_637950296049713025" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637950296049713025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637950296049713025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637950296049723022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_Liabilities_637950296049723022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_CommitmentsAndContingencies_637950296049723022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_StockholdersEquityAbstract_637950296049723022" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637950296049723022" xlink:to="us-gaap_PreferredStockValue_637950296049723022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637950296049723022" xlink:to="us-gaap_CommonStockValue_637950296049723022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637950296049723022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637950296049723022" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637950296049723022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637950296049733012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637950296049723022" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637950296049733012" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637950296049733012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637950296049723022" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637950296049733012" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637950296049733012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637950296049723022" xlink:to="us-gaap_StockholdersEquity_637950296049733012" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637950296049733012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637950296049703027" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637950296049733012" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637950296049733012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637950296049733012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637950296049733012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637950296049733012" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637950296049743022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637950296049743022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637950296049743022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637950296049743022" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637950296049743022" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637950296049743022" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_637950296049743022" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637950296049743022" xlink:to="srt_ProductOrServiceAxis_637950296049743022" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637950296049743022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637950296049743022" xlink:to="srt_ProductsAndServicesDomain_637950296049743022" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637950296049743022" xlink:to="us-gaap_ServiceMember_637950296049753023" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637950296049743022" xlink:to="us-gaap_GrantMember_637950296049753023" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637950296049743022" xlink:to="us-gaap_StatementLineItems_637950296049753023" order="2" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_RevenuesAbstract_637950296049753023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_637950296049753023" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637950296049753023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_CostsAndExpensesAbstract_637950296049753023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637950296049753023" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637950296049753023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637950296049753023" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637950296049753023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637950296049753023" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_637950296049753023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637950296049753023" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_637950296049753023" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_637950296049753023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_637950296049753023" xlink:to="us-gaap_CostsAndExpenses_637950296049753023" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_OperatingIncomeLoss_637950296049763012" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_InterestAndOtherIncome_637950296049763012" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637950296049763012" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049763012" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_EarningsPerShareBasic_637950296049763012" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_EarningsPerShareDiluted_637950296049763012" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637950296049763012" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637950296049763012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637950296049763012" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637950296049773012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296049753023" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637950296049773012" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049773012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637950296049773012" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049773012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637950296049773012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637950296049773012" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637950296049773012" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637950296049773012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637950296049773012" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637950296049773012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637950296049773012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_637950296049773012" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637950296049773012" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlow" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_635475916101371870"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637950296049773012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637950296049773012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637950296049773012" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049783028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637950296049773012" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637950296049783028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_637950296049783028" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637950296049783028" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_637950296049783028" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" xlink:to="us-gaap_ShareBasedCompensation_637950296049783028" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637950296049783028" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_637950296049783028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637950296049783028" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637950296049783028"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637950296049783028" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028" xlink:to="us-gaap_LitigationSettlementExpense_637950296049793010" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637950296049783028" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_637950296049793010" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_637950296049773012" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637950296049793010" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_637950296049793010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_637950296049793010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637950296049793010" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_637950296049793010" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637950296049793010"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_637950296049793010" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637950296049793010" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637950296049803012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637950296049803012" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_637950296049803012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637950296049803012" xlink:to="us-gaap_ProceedsFromStockPlans_637950296049803012" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637950296049803012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_637950296049803012" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637950296049803012" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637950296049803012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637950296049803012" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637950296049803012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637950296049803012" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637950296049813811"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637950296049813811" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637950296049813811"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_635475916101371870" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637950296049813811" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_637950296049813811"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637950296049813811" xlink:to="us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid_637950296049813811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_637950296049813811"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccounting_637950296049813811" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637950296049823022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637950296049823022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637950296049823022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637950296049823022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecurities" xlink:type="extended" xlink:title="10401 - Disclosure - Marketable Securities" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637950296049823022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_637950296049823022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="10501 - Disclosure - Intangible Assets" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_637950296049833032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_637950296049833032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - Other Long-Term Liabilities" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_637950296049833032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_637950296049833032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10701 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637950296049833032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637950296049833032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10801 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637950296049843031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637950296049843031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncome" xlink:type="extended" xlink:title="10901 - Disclosure - Accumulated Other Comprehensive Income" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="us-gaap_ComprehensiveIncomeNoteTextBlock_637950296049843031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNoteTextBlock_637950296049843031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="11001 - Disclosure - Revenue" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_637950296049853025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_637950296049853025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11101 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637950296049853025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637950296049853025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637950296049853025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637950296049853025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisition" xlink:type="extended" xlink:title="11301 - Disclosure - Kolltan Acquisition" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_637950296049863025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_637950296049863025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637950296049863025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637950296049863025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637950296049863025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_637950296049863025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637950296049863025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_637950296049863025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Marketable Securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_637950296049873025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_637950296049873025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Other Long-Term Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_637950296049873025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_637950296049873025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_637950296049873025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_637950296049873025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30803 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637950296049883031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637950296049883031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637950296049883031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637950296049883031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637950296049883031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637950296049883031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeTables" xlink:type="extended" xlink:title="30903 - Disclosure - Accumulated Other Comprehensive Income (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_637950296049883031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_637950296049883031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31203 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637950296049883031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637950296049883031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash" xlink:label="us-gaap_InvestmentsAndCash_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InvestmentsAndCash_637950296049893025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296049893025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637950296049893025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_637950296049893025" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049893025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049893025" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637950296049893025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637950296049893025" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637950296049893025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637950296049893025" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637950296049893025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637950296049893025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049893025" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637950296049893025" order="2" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637950296049893025" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296049903025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296049903025" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637950296049903025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049893025" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637950296049903025" order="3" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637950296049903025" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296049903025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296049903025" xlink:to="us-gaap_FairValueInputsLevel1Member_637950296049903025" order="1" use="optional" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296049903025" xlink:to="us-gaap_FairValueInputsLevel2Member_637950296049903025" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296049903025" xlink:to="us-gaap_FairValueInputsLevel3Member_637950296049903025" order="3" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296049903025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049893025" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296049903025" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637950296049975731"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296049903025" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637950296049975731" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637950296049977059"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637950296049975731" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637950296049977059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities_637950296049978387"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637950296049975731" xlink:to="us-gaap_MarketableSecurities_637950296049978387" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637950296049978387"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637950296049975731" xlink:to="us-gaap_AssetsFairValueDisclosure_637950296049978387" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_637950296049978387"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296049903025" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_637950296049978387" order="2" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637950296049978387"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_637950296049978387" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637950296049978387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_637950296049983009"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_637950296049978387" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_637950296049983009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsContingentConsiderationLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Fair Value Measurements - Contingent Consideration Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636421163747298277"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049983009"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636421163747298277" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049983009" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637950296050093012"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049983009" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637950296050093012" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637950296050093012" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296050103032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296050103032" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637950296050103032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049983009" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637950296050103032" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637950296050103032" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296050103032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637950296050103032" xlink:to="us-gaap_FairValueInputsLevel3Member_637950296050103032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296049983009" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050103032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050103032" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637950296050103032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637950296050103032" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637950296050103032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637950296050103032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637950296050103032" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_637950296050103032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_6379502960501030321"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_637950296050103032" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_6379502960501030321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Fair Value Measurements - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636421174411875217"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296050113019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636421174411875217" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296050113019" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_637950296050113019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296050113019" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_637950296050113019" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296050113019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_637950296050113019" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296050113019" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637950296050113019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_637950296050113019" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_637950296050113019" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050113019"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637950296050113019" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050113019" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050113019" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_637950296050123619" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050113019" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_637950296050123619" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050113019" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_637950296050123619" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637950296050113019" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_637950296050123619" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_637950296050123619" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637950296050123619" xlink:to="us-gaap_FinancialInstrumentAxis_637950296050123619" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050123619"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637950296050123619" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050123619" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050123619" xlink:to="us-gaap_USTreasuryAndGovernmentMember_637950296050133030" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050123619" xlink:to="us-gaap_CorporateDebtSecuritiesMember_637950296050133030" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_637950296050123619" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637950296050133030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637950296050133030" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_637950296050133030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_637950296050133030" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_637950296050133030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_637950296050133030" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost_637950296050133030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_637950296050133030" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_637950296050133030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_637950296050133030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637950296050133030" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_637950296050133030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_637950296050133030" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedGain_637950296050143030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_637950296050133030" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedGain_637950296050143030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_637950296050133030" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_637950296050143030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract" xlink:label="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637950296050133030" xlink:to="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_637950296050143030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_637950296050143030" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearGrossUnrealizedLosses_637950296050143030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_637950296050143030" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsGrossUnrealizedLosses_637950296050143030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_AvailableForSaleSecuritiesGrossUnrealizedLossesAbstract_637950296050143030" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_637950296050143030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_637950296050143030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_637950296050133030" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_637950296050143030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637950296050153407"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_637950296050143030" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637950296050153407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue" xlink:label="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_637950296050153407"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_637950296050143030" xlink:to="cldx_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue_637950296050153407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent_637950296050153407"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_637950296050143030" xlink:to="us-gaap_MarketableSecuritiesCurrent_637950296050153407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Marketable Securities - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_637950296050153407"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_637950296050153407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable_637950296050153407"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InterestReceivable_637950296050153407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIntangibleAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Intangible Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_636499653881507825"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_636499653881507825" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_637950296050163031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other Long-Term Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities_637950296050163031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_DeferredIncomeFromSaleOfTaxBenefits" xlink:label="cldx_DeferredIncomeFromSaleOfTaxBenefits_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="cldx_DeferredIncomeFromSaleOfTaxBenefits_637950296050163031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637950296050163031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_637950296050163031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilities_637950296050163031" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_637950296050163031" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637950296050163031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637950296050163031" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureOtherLongTermLiabilitiesNewJerseyTaxBenefitsDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Other Long-Term Liabilities- New Jersey tax benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_636421935241326298"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract_636421935241326298" xlink:to="us-gaap_StatementTable_637950296050173026" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637950296050173026" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_637950296050173026" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_637950296050173026" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_637950296050173026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewJerseyDivisionOfTaxationMember" xlink:label="us-gaap_NewJerseyDivisionOfTaxationMember_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_637950296050173026" xlink:to="us-gaap_NewJerseyDivisionOfTaxationMember_637950296050173026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637950296050173026" xlink:to="us-gaap_StatementLineItems_637950296050173026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296050173026" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637950296050173026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_ProceedsFromSaleOfOperatingLossesAndTaxCredits" xlink:label="cldx_ProceedsFromSaleOfOperatingLossesAndTaxCredits_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296050173026" xlink:to="cldx_ProceedsFromSaleOfOperatingLossesAndTaxCredits_637950296050173026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_PeriodForWhichBaseOfOperationsMustBeMaintained" xlink:label="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296050173026" xlink:to="cldx_PeriodForWhichBaseOfOperationsMustBeMaintained_637950296050173026" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome_637950296050173026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637950296050173026" xlink:to="us-gaap_InterestAndOtherIncome_637950296050173026" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637950296050183026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637950296050183026" xlink:to="us-gaap_StatementEquityComponentsAxis_637950296050183026" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637950296050183026" xlink:to="us-gaap_EquityComponentDomain_637950296050183026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050183026" xlink:to="us-gaap_CommonStockMember_637950296050183026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050183026" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637950296050183026" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050183026" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637950296050183026" order="3" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050183026" xlink:to="us-gaap_RetainedEarningsMember_637950296050183026" order="4" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637950296050183026" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_StockholdersEquity_637950296050193026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_CommonStockSharesIssued_637950296050193026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_637950296050193026" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_637950296050193026" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637950296050193026" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_637950296050193026" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637950296050193026" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6379502960501930261"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_StockholdersEquity_6379502960501930261" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_6379502960501930261"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="us-gaap_CommonStockSharesIssued_6379502960501930261" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_StockIssuedRemainingAuthorizedAmount" xlink:label="cldx_StockIssuedRemainingAuthorizedAmount_637950296050193026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637950296050183026" xlink:to="cldx_StockIssuedRemainingAuthorizedAmount_637950296050193026" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636499799373668190"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636499799373668190" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637950296050203016" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637950296050203016" xlink:to="us-gaap_AwardTypeAxis_637950296050203016" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637950296050203016" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637950296050203016" xlink:to="us-gaap_EmployeeStockOptionMember_637950296050203016" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637950296050203016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637950296050203016" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637950296050203016"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637950296050203016" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637950296050213030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637950296050213030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637950296050213030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637950296050213030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637950296050213030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637950296050213030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637950296050213030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637950296050213030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637950296050213030"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637950296050213030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637950296050223031" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637950296050203016" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637950296050223031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637950296050223031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637950296050223031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637950296050223031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6379502960502230311"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6379502960502230311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637950296050223031"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637950296050223031" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637950296050233015"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637950296050223031" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637950296050233015" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637950296050233015"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637950296050203016" xlink:to="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637950296050233015" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637950296050233015"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637950296050233015" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637950296050233015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637950296050233015"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637950296050233015" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_637950296050233015" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637950296050233015"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cldx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_637950296050233015" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637950296050233015" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationEmployeeStockOptionAndIncentivePlanActivityAdditionalInformationDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Stock-Based Compensation - Employee Stock Option and Incentive Plan Activity Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636499806868818021"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636499806868818021" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637950296050243032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_637950296050243032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637950296050243032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637950296050243032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_637950296050233015" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637950296050243032" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Stock-Based Compensation - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050243032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050243032" xlink:to="us-gaap_IncomeStatementLocationAxis_637950296050243032" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637950296050243032" xlink:to="us-gaap_IncomeStatementLocationDomain_637950296050243032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637950296050243032"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637950296050243032" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637950296050243032" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637950296050243032" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637950296050253025" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050243032" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637950296050253025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637950296050253025" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637950296050253025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureStockBasedCompensationValuationDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Stock-Based Compensation - Valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636495621397615096"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636495621397615096" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050253025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050253025" xlink:to="us-gaap_AwardTypeAxis_637950296050253025" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637950296050253025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637950296050253025" xlink:to="us-gaap_EmployeeStockOptionMember_637950296050253025" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637950296050253025" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637950296050253025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637950296050253025"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637950296050253025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637950296050263023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637950296050263023" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637950296050263023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637950296050263023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637950296050263023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637950296050263023" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637950296050263023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637950296050263023" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637950296050263023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637950296050253025" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637950296050263023" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureAccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Accumulated Other Comprehensive Income (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_637950296050263023"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_637950296050263023" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_637950296050263023" xlink:to="us-gaap_StatementEquityComponentsAxis_637950296050273034" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637950296050273034" xlink:to="us-gaap_EquityComponentDomain_637950296050273034" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050273034" xlink:to="us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_637950296050273034" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="us-gaap_AccumulatedTranslationAdjustmentMember_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050273034" xlink:to="us-gaap_AccumulatedTranslationAdjustmentMember_637950296050273034" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637950296050273034" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637950296050273034" order="3" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_637950296050263023" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_637950296050273034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_637950296050273034" xlink:to="us-gaap_StockholdersEquity_637950296050273034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_637950296050273034" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_637950296050273034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6379502960502730341"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_637950296050273034" xlink:to="us-gaap_StockholdersEquity_6379502960502730341" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_637950296050273034"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_637950296050273034" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_637950296050273034" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637950296050283021" order="1" use="optional" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637950296050283021" xlink:to="srt_MajorCustomersAxis_637950296050283021" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_637950296050283021" xlink:to="srt_NameOfMajorCustomerDomain_637950296050283021" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_RockefellerUniversityAndGileadSciencesMember" xlink:label="cldx_RockefellerUniversityAndGileadSciencesMember_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_637950296050283021" xlink:to="cldx_RockefellerUniversityAndGileadSciencesMember_637950296050283021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637950296050283021" xlink:to="srt_ProductOrServiceAxis_637950296050283021" order="2" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637950296050283021" xlink:to="srt_ProductsAndServicesDomain_637950296050283021" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637950296050283021" xlink:to="us-gaap_ServiceMember_637950296050283021" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637950296050283021" xlink:to="us-gaap_GrantMember_637950296050283021" order="2" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637950296050283021" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637950296050283021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637950296050283021"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637950296050283021" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_637950296050283021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637950296050293020"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637950296050283021" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637950296050293020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_637950296050293020"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637950296050283021" xlink:to="us-gaap_ContractWithCustomerAssetNet_637950296050293020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_637950296050293020"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637950296050283021" xlink:to="us-gaap_ContractWithCustomerLiability_637950296050293020" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_637950296050293020"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities_637950296050293020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637950296050293020"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637950296050293020" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637950296050293020"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637950296050293020" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637950296050293020" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637950296050293020" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637950296050303026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637950296050303026" xlink:to="us-gaap_EmployeeStockOptionMember_637950296050303026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637950296050293020" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637950296050303026" order="2" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637950296050303026" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637950296050303026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | </presentationLink> |
| <presentationLink xlink:role="http://www.celldextherapeutics.com/role/DisclosureKolltanAcquisitionDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Kolltan Acquisition (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract_636501377334943236"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract_636501377334943236" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026" xlink:to="us-gaap_BusinessAcquisitionAxis_637950296050303026" order="1" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637950296050303026" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637950296050303026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_KolltanPharmaceuticalsMember" xlink:label="cldx_KolltanPharmaceuticalsMember_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637950296050303026" xlink:to="cldx_KolltanPharmaceuticalsMember_637950296050303026" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_637950296050303026"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_637950296050303026" order="2" use="optional" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_637950296050303026" xlink:to="us-gaap_ContingentConsiderationTypeDomain_637950296050313022" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_ContingentMilestoneMember" xlink:label="cldx_ContingentMilestoneMember_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_637950296050313022" xlink:to="cldx_ContingentMilestoneMember_637950296050313022" order="1" use="optional"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026" xlink:to="us-gaap_FinancialInstrumentAxis_637950296050313022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637950296050313022" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050313022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_ClinicalTrailMember" xlink:label="cldx_ClinicalTrailMember_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637950296050313022" xlink:to="cldx_ClinicalTrailMember_637950296050313022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassAxis" xlink:label="us-gaap_UnderlyingAssetClassAxis_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026" xlink:to="us-gaap_UnderlyingAssetClassAxis_637950296050313022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnderlyingAssetClassDomain" xlink:label="us-gaap_UnderlyingAssetClassDomain_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassAxis_637950296050313022" xlink:to="us-gaap_UnderlyingAssetClassDomain_637950296050313022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_EuropeanMedicinesAgencyMember" xlink:label="cldx_EuropeanMedicinesAgencyMember_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnderlyingAssetClassDomain_637950296050313022" xlink:to="cldx_EuropeanMedicinesAgencyMember_637950296050313022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_637950296050303026" xlink:to="us-gaap_BusinessAcquisitionLineItems_637950296050313022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637950296050313022" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_637950296050313022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_637950296050313022"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637950296050313022" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_637950296050313022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid" xlink:label="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid_637950296050323013"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637950296050313022" xlink:to="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPaid_637950296050323013" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_637950296050323013"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637950296050313022" xlink:to="us-gaap_LitigationSettlementExpense_637950296050323013" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement" xlink:label="cldx_BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement_637950296050323013"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637950296050313022" xlink:to="cldx_BusinessCombinationContingentConsiderationContractualCreditInMergerAgreement_637950296050323013" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | <loc xlink:type="locator" xlink:href="cldx-20220630.xsd#cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable" xlink:label="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable_637950296050323013"/> |
| | <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_637950296050313022" xlink:to="cldx_BusinessCombinationContingentConsiderationSettlementAgreementAmountPayable_637950296050323013" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1"/> |
| | </presentationLink> |
| </link:linkbase> |